EBSEmergent BioSolutions Inc.

$433M

FY 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$561M+14.8% YoY

Gross Profit

$284M50.6% margin

Operating Income

$124M22.2% margin

Net Income

$83M14.7% margin

EPS (Diluted)

$1.71

Cash Flow

Operating Cash Flow

$208M

Free Cash Flow

$153M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$158M

Stockholders' Equity

$912M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$561M	$489M	+14.8%
Gross Profit	$284M	$245M	+15.8%
Operating Income	$124M	$106M	+17.8%
Net Income	$83M	$52M	+59.5%

EBS FY 2017 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena